Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Blogs about Biotechnology, Pharmaceutical and Healthcare

19:43 EDT 31st July 2014 | BioPortfolio

Read the latest opinions - blogs from pharmaceutical and life science industry experts.

Showing News Articles 1–25 of 53,000+

Thursday 31st July 2014

La Jolla Pharmaceutical Company’s (LJPC): Mr. Everything Keeps on Buying, and Buying, and…

La Jolla Pharmaceutical Company’s (NASDAQ:LJPC) Chief Exec. Officer, President, Principal Financial Officer, Principal Accounting Officer, Sec. and Director, Dr. George F. Tidmarsh M.D., Ph.D., bought 19,000 LJPC shares at $10.50 for a total investment of $199,500.[More...]

Xencor's (XNCR) CEO Bassil Dahiyat on Q2 2014 Results - Earnings Call Transcript

Xencor, Inc (NASDAQ:XNCR) Q2 2014 Earnings Conference Call July 31, 2014 16:30 ET Executives Deanne Tockey - Stern, IR Bassil Dahiyat - President & CEO John Kuch - VP, Finance Analysts Michael Schmidt - Leerink Partners Christopher Marai - Oppenheimer David Nierengarten - Wedbush Securities Presentation Operator Good afternoon and welcome to the Xencor Second Quarter 2014...

Sanofi's (SNY) CEO Chris Viehbacher on Q2 2014 Results - Earnings Call Transcript

Sanofi (NYSE:SNY) Q2 2014 Earnings Conference Call July 31, 2014 8:30 a.m. ET Executives Sébastien Martel - Vice President of Investor Relations Chris Viehbacher - Chairman, CEO Jérôme Contamine -EVP, CFO Elias Zerhouni - President, Global R&D Analysts Michael Leuchten – Barclays Graham Parry - Bank of America Merrill Lynch Peter Verdult – Citi Tim Anderson - Sanford Bernstein M...

ME/CFS interviews on BBC Radio Gloucestershire today | 31 July 2014

Interviews with 21-year-old Lindsey Shorter, from Cheltenham, and MEA medical adviser Dr Charles Shepherd.

U.S. FDA Cites Problems With Cadila Drug-Production Plant In India

The U.S. FDA has questioned drug-production processes at yet another India plant, this one operated by Cadila Healthcare.

Lupin Seeks Major Acquisitions, Won't Say If That Includes GSK Brands

CEO Vinita Gupta would not confirm Lupin is one of the bidders for some of GlaxoSmithKline's older brands, but he did say his firm is seeking acquisitions that would give it therapeutic and geographical edges.

Novartis Japan Apologizes For Not Reporting Leukemia Drug Side Effects

Already under fire in Japan over allegations of manipulated data, Novartis Pharma KK has been forced to apologize for a delay in reporting side effects associated with its Gleevec (imatinib) and Tasign (nilotinib) leukemia drugs.

PET Scans of Brain for Tau Protein an Early Predictor of Memory Loss

For the past few years, one of the most important research areas in radiology has been the search for reliable imaging techniques to diagnose early Alzheimer's disease. This has involved attempts to identify deposits of both beta amyloid and tau prot...

Baxter’s HyQvia Rises Above FDA’s Theoretical Long-Term Concerns

Agency officials say long-term immunogenicity issues could manifest among patients taking proposed primary immunodeficiency disorder treatment, but advisory committee concludes risk can be managed.

Consumer Reports slams opioids

Opioids overprescribed; Zohydro approval should be reconsidered, magazine says.

High Valuations Sideline Sanofi From The M&A Game…For Now

Sanofi CEO Chris Viehbacher said the company is focusing mainly on bolt-on acquisitions because valuations for targets have ballooned so significantly. Inversion deals are further inflating assets, he said.

Johnson & Johnson Has Enough Catalysts To Beat The Market

By Anup Singh:Johnson & Johnson (NYSE:JNJ) is enjoying a good time in 2014, appreciating 10% and beating the broader market so far. The healthcare major delivered strong second-quarter results, driven by the strong performances of over-the-counter products, skin care and baby care products. Additionally, international sales of its oral care and feminine protection products were strong. Besides...

Sanofi Investing €700 Million Ahead Of Launches

Sanofi is ramping up for several product launches in the next 12 months, including a next-generation basal insulin Toujeo, Lemtrada for multiple sclerosis, Cerdelga for Gaucher’s disease and Praluent for high cholesterol.

Teva Pharmaceutical Industries' (TEVA) CEO Erez Vigodman on Q2 2014 Results - Earnings Call Transcript

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Q2 2014 Earnings Conference Call July 31, 2014 8:00 am ET Executives Kevin C. Mannix - VP, Head of Investor Relations Erez Vigodman - President and CEO Eyal Desheh - Group EVP and CFO Richard S. Egosi - Group EVP, Chief Legal Officer and Company Secretary Michael Hayden - President of Global R&D and Chief Scientific Officer Sigurdur Olafss...

Heartware International's (HTWR) CEO Doug Godshall on Q2 2014 Results - Earnings Call Transcript

Heartware International, Inc. (NASDAQ:HTWR) Q2 2014 Earnings Conference Call July 31, 2014 08:00 ET Executives Chris Taylor - Vice President, Investor Relations Doug Godshall - President and Chief Executive Officer Peter McAree - Chief Financial Officer Analysts Chris Pasquale - JPMorgan Matthew Taylor - Barclays Jason Mills - Canaccord Genuity Jason Bedford - Raymond James Larry Biegelsen...

AstraZeneca’s Brilinta Gives Brilliant Sales Performance

AstraZeneca’s cardiovascular drug Brilinta – one of the group’s five key growth platforms - seems to have turned the corner to give a stellar performance in the second quarter – particularly in the crucial US market.

West Coast Biotech Roundup: Amgen Layoffs, Avalanche, Venter & More

Momenta's (MNTA) CEO Craig Wheeler on Q2 2014 Results - Earnings Call Transcript

Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) Q2 2014 Results Earnings Conference Call July 31, 2014 10:00 AM ET Executives Eric Shaff - Vice President, Corporate Finance Craig Wheeler - President and CEO Rick Shea - Chief Financial Officer Analysts Gary Nachman - Goldman Sachs Sumant Kulkarni - Bank of America David Risinger - Morgan Stanley Eric Schmidt - Cowen and Company Jason Gerberry -...

Cigna's (CI) CEO David Cordani on Q2 2014 Results - Earnings Call Transcript

Cigna (NYSE:CI) Q2 2014 Earnings Call July 31, 2014 8:30 am ET Executives Edwin J. Detrick - Vice President of Investor Relations David M. Cordani - Chief Executive Officer, President, Director and Member of Executive Committee Thomas A. McCarthy - Chief Financial Officer and Executive Vice President Analysts Matthew Borsch - Goldman Sachs Group Inc., Research Division Justin Lake - JP Mor...

Alkermes' (ALKS) CEO Richard Pops on Q2 2014 Results - Earnings Call Transcript

Alkermes Plc (NASDAQ:ALKS) Q2 2014 Earnings Conference Call July 31 2014 8:30 AM ET Executives Rebecca Peterson- SVP, Corporate Communication Jim Frates - SVP and CFO Richard Pops - Chairman and CEO Analysts Ari Jaha - Credit Suisse Cory Kasimov - JPMorgan Jonathan Eckard - Citi Bevin Anil - Jefferies Jonathan Chang - Leerink Partners Mario Corso - Mizuho USA. Sarah - Bank of America...

Woman takes first steps in NINE YEARS after being struck down by ME | Daily Express | 31 July 2014

Jessica takes her first steps in nine years at the Burrswood Hospital (photo: Caters News).

Incyte's (INCY) CEO Hervé Hoppenot on Q2 2014 Results - Earnings Call Transcript

Incyte Corporation (NASDAQ:INCY) Q2 2014 Earnings Conference Call July 31, 2014 08:30 AM ET Executives Pamela Murphy - VP of IR Hervé Hoppenot - President and CEO Jim Daly - CCO Dave Hastings - CFO Rich Levy - CMO and Head of Drug Development Reid Huber - CSO Analysts Eric Schmidt - Cowen & Company Josh Schimmer - Piper Jaffray Matt Roden - UBS Whitney Ijem - JPMorgan Chase...

Raleigh-Durham Roundup: Targacept, Causam Energy, Merz, & Google

Targacept fails another clinical trial and suggests a possible change in course. Meanwhile, Causam Energy announces an acquisition and Merz completes one. Read about these and other headlines in this roundup of North Carolina technology and biotech n...

IT strategy for health plans: Interview with ikaSystems CEO Joe Marabito

Health plans are investing in new information technology capabilities to meet the requirements of the Affordable Care Act and to differentiate themselves from the competition. Slowly but surely they’re moving from inflexible legacy, mainframe...

Good Value Johnson & Johnson Could Outperform This Peer

By Team Money Research:In this article we're focusing on Johnson & Johnson (NYSE:JNJ) and comparing it to a similar sized rival in Novartis (NYSE:NVS). Although the two companies have an ocean between them, with JNJ being listed in the US and Novartis in Switzerland, the two stocks are of a similar size, with JNJ having a market cap of $288 billion and Novartis having a market cap of $213 bill...

Search BioPortfolio: